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ABSTRACT 
 
This study investigated the effect of the serotonin selective reuptake inhibitors (SSRIs) 
fluoxetine, sertraline, fluvoxamine and the tricyclic antidepressant (TCA) impiramine on oxi-
dative stress in brain and liver induced by lipopolysaccharide administration in mice. Each 
drug was administered subcutaneously at doses of 10 or 20 mg/kg, for two days prior to in-
traperitoneal (i.p.) administration of lipopolysaccharide E (LPS: 200 µg/kg). Mice were 
euthanized 4 h after administration of the lipopolysaccharide. Lipid peroxidation (malondial-
dehyde; MDA), reduced glutathione (GSH) and nitric oxide (nitrite/nitrate) concentrations 
were measured in brain and liver.  
Results: The administration of lipopolysaccharide increased oxidative stress in brain and liv-
er; it increased brain MDA by 36.1 and liver MDA by 159.8 %. GSH decreased by 34.1 % 
and 64.8 % and nitric oxide increased by 78.7 % and 103.8 % in brain and liver, respectively. 
In brain, MDA decreased after the administration of sertraline and by the lower dose of fluo-
xetine or fluvoxamine, but increased after the higher dose of imipramine. Reduced glutathione 
increased after sertraline, fluvoxamine and the lower dose of fluoxetine or imipramine. Nitric 
oxide decreased by sertraline, fluoxetine, fluvoxamine and by the lower dose of imipramine. 
In the liver, all drugs decreased MDA and increased GSH level. Nitric oxide is decreased by 
sertraline, fluvoxamine and by the lower dose of fluoxetine or imipramine. It is concluded 
that, during mild systemic inflammatory illness induced by peripheral bacterial endotoxin in-
jection, the SSRIs fluoxetine, sertraline and fluvoxamine reduced, while the TCA impiramine 
increased oxidative stress induced in the brain. The SSRIs as well as imipramine reduced oxi-
dative stress due to lipopolysaccharide in liver tissue.  
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INTRODUCTION 
The last decade has witnessed the intro-
duction of several new antidepressant drugs 
for the pharmacological management of 
depressive disorders. In particular, the sero-
tonin reuptake inhibitors (SSRIs) fluoxet-
ine, sertraline, fluvoxamine, paroxetine and 
citaopram are the most commonly pre-
scribed antidepressant drugs nowadays. 
These agents have replaced the older classic 
tricyclic antidepressant (TCA) drugs since 
they are well tolerated and generally lack 
the anticholinergic and antihistaminic side 
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effects of the tricyclic agents. The SSRIs 
are believed to selectively inhibit neuronal 
reuptake of serotonin, thereby increasing its 
concentration in the synapse (Fuller, 1994). 
This effect results in alleviation of the 
symptoms of depression (Gibbons, 2000). 
The reuptake of other neurotransmitters is 
inhibited as well by some members of this 
group of drugs. Sertraline for example also 
inhibits dopamine reuptake to a degree that 
possibly have clinical consequences (Good-
nick and Goldstein, 1998; Sánchez and Hyt-
tel, 1999; Kitaichi et al., 2010). There is 
also an evidence suggesting inhibition of 
noradrenaline and dopamine reuptake by 
fluoxetine (Pozzi et al., 1999; Bymaster et 
al., 2002). The tricyclic drug imipramine, 
on the other hand, inhibits both noradrena-
line and serotonin reuptake (Felton et al., 
2003). 
Studies have suggested a neuroprotec-
tive and an antiapoptotic effect for a num-
ber of antidepressant drugs (Drzyzga et al., 
2009; Peng et al., 2008). In culture, fluoxet-
ine or the TCA amitriptyline protected rat 
pheochromocytoma (PC12) cells against 
the neurotoxicity of  hydrogen peroxide 
(Kolla et al., 2005). The SSRI escitalopram 
protected against ischemia-induced neu-
ronal death in the gerbil hippocampal CA1 
region after transient cerebral ischemia (Lee 
et al., 2011). In vitro, imipramine as well as 
fluoxetine increased the survival rate of 
neural stem cells (Peng et al., 2008; Chen et 
al., 2007). In addition, the effect of antide-
pressant drugs on the liver integrity in the 
healthy and diseased liver is of particular 
importance. This is because (1) the liver is 
the site of metabolism for many of these 
drugs; (2) depression is common in patients 
with chronic liver disease and can compli-
cate antiviral therapy with ribavirin-
interferon (Lang et al., 2003; Cai et al., 
2005; Cozzi et al., 2006) and therefore anti-
depressant drugs are also prescribed in 
these patients (Gleason et al., 2002; Schäfer 
et al., 2000); (3) serotonin plays an impor-
tant role in pathogenesis of liver injury as 
well as in liver regeneration (Lang et al., 
2008; Lesurtel et al., 2008); (4) alterations 
in brain neurotransmitters have been impli-
cated in the pathogenesis of hepatic en-
cephalopathy (Lozeva-Thomas, 2004), a 
serious neuropsychiatric complication of 
both acute and chronic liver disease.  
The administration of lipopolysaccha-
ride endotoxin is a widely used model to 
study the effect of systemic endotoxaemia 
and the resultant systemic inflammatory 
responses on tissue function. The admini-
stration of lipopolysaccharide endotoxin to 
experimental animals elicits increased oxi-
dative stress. The model is also used to 
study the effect of peripheral inflammatory 
stimuli on brain function. Therefore, it 
looked pertinent to study the effect of the 
SSRIs compared with the TCA imipramine 
on oxidative stress in brain and liver after 
endotoxin treatment. 
 
MATERIALS AND METHODS 
Animals 
Swiss male albino mice 20-22 g of body 
weight (age: 5-6 weeks) were used. Mice 
were obtained from animal house colony of 
the National Research Centre (Cairo, 
Egypt). Standard laboratory food and water 
were provided ad libitum. Animal proce-
dures were performed in accordance with 
the Ethics Committee of the National Re-
search Centre and followed the recommen-
dations of the National Institutes of Health 
Guide for Care and Use of Laboratory An-
imals (Publication No. 85-23, revised 
1985). Equal groups of 6 mice each were 
used in all experiments.  
 
Drugs and chemicals 
Lipopolysaccharide derived from Es-
cherichia coli (Serotype 055: B5, Sigma, St 
Louis, MO, USA) was used and dissolved 
in sterile saline, aliquoted, and frozen at 
−20 °C. Fluoxetine hydrochloride (Amoun 
Pharmaceutical Co., Cairo, A.R.E.), ser-
traline hydrochloride (Pfizer Egypt, Cairo, 
A.R.E.), imipramine hydrochloride (Novar-
tis Pharma, Cairo, A.R.E.) and fluvoxamine 
maleate (Pharco Pharmaceuticals, Alexan-
dria, A.R.E.) were used and dissolved in 
isotonic (0.9 % NaCl) saline solution im-
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mediately before use. The doses of drugs 
employed were based upon the human dose 
after conversion to that of mice according 
to Paget and Barnes (1964) conversion ta-
bles. 
 
Study design 
Mice were divided into 8 equal groups 
(6 mice each). Mice were treated with 
fluoxetine (10, 20 mg/kg) (groups 1, 2), ser-
traline (10, 20 mg/kg) (groups 3, 4), flu-
voxamine (10, 20 mg/kg) (groups 5, 6), im-
piramine (10, 20 mg/kg) (groups 7, 8) or 
saline (group 9, control) once daily orally 
for 2 days before and just before lipopoly-
saccharide injection (200 mg/kg, i.p.). In 
addition, an eighth group (n=6) received 
only saline (-ve control). Mice were eutha-
nized 4 h after lipopolysaccharide by de-
capitation under ether anaesthesia. Mice 
had free access to food and drinking water 
during the study. At the end of the experi-
ments, brains and livers were removed, 
washed with ice-cold saline solution (0.9 % 
NaCl) and stored at -80 ºC for further de-
termination of biochemical parameters. 
They were homogenised with 0.1 M phos-
phate buffer saline at pH 7.4, to give a final 
concentration of 10 % w/v for the bio-
chemical assays.  
 
Biochemical assessment 
Determination of lipid peroxidation 
Lipid peroxidation was assayed by mea-
suring the level of malondialdehyde 
(MDA). Malondialdehyde forms a 1:2 ad-
duct with thiobarbituric acid which can be 
measured by spectrophotometry. Malondi-
aldehyde was determined by measuring thi-
obarbituric reactive species using the 
method of Ruiz-Larrea et al. (1994), in 
which the thiobarbituric acid reactive sub-
stances react with thiobarbituric acid to pro-
duce a red colored complex having peak 
absorbance at 532 nm. 
 
Determination of reduced glutathione  
Reduced glutathione (GSH) was deter-
mined by Ellman's method (1959). The pro-
cedure is based on the reduction of Ell-
man´s reagent by –SH groups of GSH to 
form 2-nitro-s-mercaptobenzoic acid. The 
nitromercaptobenzoic acid anion has an in-
tense yellow color which can be determined 
spectrophotometrically.  
 
Determination of nitric oxide  
Nitric oxide measured as nitrite was de-
termined by using Griess reagent, according 
to the method of Moshage et al. (1995) 
where nitrite, stable end product of nitric 
oxide radical, is mostly used as indicator 
for the production of nitric oxide.  
 
Statistical analysis 
Data are expressed as mean ± SEM. The 
data were analyzed by one way ANOVA 
followed by Duncan’s multiple range test, 
using SPSS software (SAS Institute Inc., 
Cary, NC). A probability value of less than 
0.05 was considered statistically significant.  
 
RESULTS 
Effect of antidepressant drugs on brain 
oxidative stress 
Lipid peroxidation  
The administration of lipopolysaccha-
ride significantly increased brain MDA by 
36.1 % (42.18 ± 1.67 vs 31.0 ± 1.54 nmol/g, 
p<0.05). Fluoxetine or fluvoxamine given 
at 10 mg/kg, decreased brain MDA by 14.6 
and 28.6 %, respectively (36.03 ± 2.48 and 
30.1 ± 2.37 vs 42.18 ± 1.67 nmol/g, 
p<0.05). The higher dose of either drug, 
however, did not significantly alter MDA 
level. Sertraline administered at 10 or 
20 mg/kg decreased MDA by 40.7 and 
30.0 %, respectively (24.99 ± 1.23 and 
29.52 ± 2.12 vs 42.18 ± 1.67 nmol/g, 
p<0.05). Brain MDA was not altered by 
imipramine at 10 mg/kg. The higher dose of 
the drug, however, significantly increased 
the level of MDA by 118.1 % (91.98 ± 3.19 
vs 42.18 ± 1.67 nmol/g, p<0.05) (Figure 1). 
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Figure 1: Effect of  antidepressant drugs on the 
brain tissue level of malondialdehyde (MDA; 
nmol/g tissue) in lipopolysaccharide-treated 
mice. The plus sign indicates significant change 
from the saline group. Asterisks indicate signifi-
cant change from saline group and between 
different groups as indicated. 
 
Reduced glutathione 
The administration of lipopolysaccha-
ride significantly decreased brain GSH by 
34.1 % (2.11 ± 0.16 vs 3.20 ± 0.12 µmol/g, 
p<0.05) compared with the saline control 
group. Significant increase in the level of 
GSH was observed after fluoxetine treat-
ment at 10 mg/kg (27 % increase; 2.68 ± 
0.14 vs 2.11 ± 0.16 µmol/g, p<0.05). The 
higher dose of the drug had no significant 
effect on GSH level. Reduced glutathione 
significantly increased by 34.6 and 20.4 % 
by sertraline at 10 and 20 mg/kg (2.83 ± 
0.15 and 2.54 ± 0.10 vs control value of 
2.11 ± 0.16 µmol/g, p<0.05) and by 22.7 
and 21.3 % by fluvoxamine at 10 and 
20 mg/kg (2.59 ± 0.18 and 2.56 ± 0.11 vs 
control value of 2.11 ± 0.16 µmol/g, 
p<0.05). Imipramine administered at 
10 mg/kg increased GSH by 46.4 %. The 
higher dose of imipramine, however, re-
sulted in 18.5 % increase in GSH %, com-
pared with the LPS control group. Values 
of GSH were: 3.09 ± 0.16 and 2.5 ± 0.19 
for imipramine doses of 10 and 20 mg/kg, 
respectively vs LPS control value of 2.11 ± 
0.16 µmol/g, p<0.05 (Figure 2). 
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Figure 2: Effect of antidepressant drugs on the 
brain tissue level of reduced glutathione (GSH: 
µmol/g tissue) in lipopolysaccharide-treated 
mice. The plus sign indicates significant change 
from the saline group. Asterisks indicate signifi-
cant change from saline group and between 
different groups as indicated. 
 
Nitric oxide 
The level of nitric oxide increased by 
78.7 % after lipopolysaccharide injection 
compared with the saline control group 
(39.32 ± 1.08 vs 22.0 ± 1.40 µmol/g, 
p<0.05). In lipopolysaccharide-treated rats, 
nitric oxide level was markedly and signifi-
cantly decreased by fluoxetine, sertraline or 
fluvoxamine. Nitric oxide decreased by 44 
and 30.1 % by fluoxetine at 10 and 
20 mg/kg (22.0 ± 0.6 and 27.5 ± 1.38 vs 
control value of 39.32 ± 1.08 µmol/g, 
p<0.05). It decreased by 36.7 and 38.7 % 
by sertraline at 10 and 20 mg/kg (24.9 ± 
1.24 and 24.1 ± 2.00 vs control value of 
39.32 ± 1.08 µmol/g, p<0.05) and by 35.4 
and 50.4 % by fluvoxamine at 10 and 
20 mg/kg (25.4 ± 1.30 and 19.5 ± 0.94 vs  
control value of 39.32 ± 1.08 µmol/g, 
p<0.05). The level of nitric oxide was sig-
nificantly decreased by 43.3 after the ad-
ministration of imipramine at 10 mg/kg. 
The higher dose of imipramine, however, 
increased nitric oxide by 25.4 %, compared 
with the LPS control group. Values of nitric 
oxide were: 22.3 ± 1.14 and 49.3 ± 2.27 for 
imipramine doses of 10 and 20 mg/kg, re-
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spectively vs LPS control value of 39.32 ± 
1.08 µmol/g, p<0.05 (Figure 3). 
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Figure 3: Effect of antidepressant drugs on the 
brain tissue level of nitric oxide (nitrite/nitrate; 
µmol/g tissue) in lipopolysaccharide-treated 
mice. The plus sign indicates significant change 
from the saline group. Asterisks indicate signifi-
cant change from saline group and between 
different groups as indicated. 
 
Effect of antidepressant drugs on liver 
oxidative stress 
Lipid peroxidation  
The level of MDA was significantly in-
creased by 159.8 % by the administration of 
LPS (64.94 ± 4.3 vs 25.0 ± 2.0 nmol/g tis-
sue; p<0.05). In LPS-treated mice, MDA 
significantly decreased by fluoxetine (-52.3 
and -52.4 %), sertraline (-28.6 and -
37.6 %), fluvoxamine (-56.8 and -60.5 %), 
or imipramine (-39.1 and -48.2 %) given at 
doses of 10 and 20 mg/kg, compared with 
the LPS control group. Values of MDA 
were: 30.96 ± 2.47 and 30.93 ± 2.23 for 
fluoxetine doses of 10 and 20 mg/kg; 46.36 
± 3.17 and 40.5 ± 3.11 for sertraline doses 
of 10 and 20 mg/kg; 28.07 ± 1.92 and 25.63 
± 1.67 for fluvoxamine doses of 10 and 
20 mg/kg; 39.58 ± 2.62 and 33.62 ± 2.13 
for imipramine doses of 10 and 20 mg/kg, 
respectively vs LPS control value of 64.94 
± 4.3 nmol/g, p<0.05 (Figure 4). 
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Figure 4: Effect of  antidepressant drugs on the 
liver tissue level of malondialdehyde (MDA; 
nmol/g tissue) in lipopolysaccharide-treated 
mice. The plus sign indicates significant change 
from the saline group. Asterisks indicate signifi-
cant change from saline group and between 
different groups as indicated. 
 
Reduced glutathione 
The level of GSH was reduced by 
64.8 % after LPS treatment (2.2 ± 0.18 vs 
6.25 ± 0.39 µmol/g, p<0.05). In LPS-
treated mice, Reduced glutathione was sig-
nificantly increased by fluoxetine (54.5 and 
49.5 %), sertraline (44.1 and 65.4 %), flu-
voxamine (26.4 and 62.7 %), or imipramine 
(36.4 and 160.9 %) given at doses of 10 and 
20 mg/kg, compared with the LPS control 
group. Values of GSH were: 3.4 ± 0.26 and 
2.29 ± 0.21 for fluoxetine doses of 10 and 
20 mg/kg; 3.17 ± 0.26 and 3.64 ± 0.21 for 
sertraline doses of 10 and 20 mg/kg; 2.78 ± 
0.18 and 3.58 ± 0.27 for fluvoxamine doses 
of 10 and 20 mg/kg; 3.00 ± 0.20 and 5.74 ± 
0.38 for imipramine doses of 10 and 
20 mg/kg, respectively vs LPS control value 
of 2.2 ± 0.18 µmol/g, p<0.05 (Figure 5). 
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Figure 5: Effect of antidepressant drugs on the 
liver tissue level of reduced glutathione (GSH: 
µmol/g tissue) in lipopolysaccharide-treated 
mice. The plus sign indicates significant change 
from the saline group. Asterisks indicate signifi-
cant change from saline group and between 
different groups as indicated. 
 
Nitric oxide 
Nitric oxide increased by 103.8 % after 
LPS administration (27.0 ± 1.3 vs 13.25 ± 
1.05 µmol/g, p<0.05) compared with the 
saline control group. The lower dose of flu-
oxetine decreased nitric oxide by 26.3 % 
compared with the LPS control group 
(19.89 ± 0.85 vs 27.0 ± 1.3 µmol/g, 
p<0.05). However, no significant effect on 
the level of nitric oxide was observed in 
mice treated with fluoxetine at 20 mg/kg. 
Nitric oxide decreased by 33.4 and 23.5 % 
by sertraline at doses of 10 and 20 mg/kg, 
respectively (17.98 ± 0.86 and 20.65 ± 1.32 
vs 27.0 ± 1.3 µmol/g, p<0.05) and was re-
stored to near normal value by fluvoxamine 
treatment. The level of nitric oxide de-
creased by 16.3 % by the lower dose of im-
ipramine (22.6 ± 0.62 vs 27.0 ± 1.3 µmol/g, 
p<0.05). The effect of imipramine at the 
highest dose of 20 mg/kg was not signifi-
cant (Figure 6). 
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Figure 6: Effect of antidepressant drugs on the 
liver tissue level of nitric oxide (nitrite/nitrate; 
µmol/g tissue) in lipopolysaccharide-treated 
mice. The plus sign indicates significant change 
from the saline group. Asterisks indicate signifi-
cant change from saline group and between 
different groups as indicated. 
 
DISCUSSION 
In the present study, the induction of 
mild systemic inflammation by peripheral 
administration of a small dose of LPS en-
dotoxin increased oxidative stress in both 
the brain and liver. Malondialdehyde a 
marker of lipid peroxidation activity (Gut-
teridge, 1995) is increased in both organs. 
This was associated with marked and sig-
nificant decrease in the level of reduced 
glutathione, an important antioxidant de-
fense mechanism. LPS administration re-
sulted also in markedly increased nitric ox-
ide levels in brain and liver. The signifi-
cance of these findings implies that mild 
systemic inflammation by itself impairs an-
tioxidant defense mechanisms and conse-
quently make the brain (or liver) more sus-
ceptible to further oxidative insults. Studies 
have shown decreased brain reduced glu-
tathione and glutathione reductase activity 
in rats after the administration of lipopoly-
saccharide (1 mg/kg, i.p.) (Jacewicz et al., 
2009). Similarly, a single intraperitoneal 
dose of lipopolysaccharide (250 µg/mouse) 
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was associated with GSH depletion, 
cyclooxygenase-2 expression, lipid peroxi-
dation and impairment in mitochondrial re-
dox activity (Noble et al., 2007). Thus en-
dotoxin-induced peripheral systemic in-
flammation can affect brain functions. In 
this context, studies have also shown that 
induction of systemic inflammation by in-
travenous or intraperitoneal lipopolysaccha-
ride injection causes brain inflammation. 
Thus, Jeong et al. (2010) have shown that 
acute induction of systemic inflammation 
with intravenous lipopolysaccharide at 100 
or 500 µg/kg causes brain inflammation 
although this was not sufficient to induce 
neuronal injury. Other researchers reported 
neuronal damage after higher dose of the 
endotoxin (Qin et al., 2007). It has also 
been shown that LPS (50 µg/kg, i.p.)-
induced peripheral inflammation exacer-
bated ischaemic hippocampal cell loss after 
global brain ischaemia, independently of 
hippocampal pro-inflammatory cytokine 
production, hippocampal microglial activa-
tion or temperature changes (Spencer et al., 
2007). These observations are important in 
view of the evidence linking both increased 
oxidative stress and inflammation in the 
pathogenesis of several neurological, neu-
ropsychiatric and neurodegenerative disor-
ders such as Parkinson's disease and Alz-
heimer's disease, schizophrenia as well as 
depression (Maes, 2008; Wood et al., 
2009).  
The present study also provided an evi-
dence for a beneficial effect for the SSRIs 
fluoxetine, fluovoxamine or sertraline in 
decreasing brain oxidative stress induced by 
endotoxin administration. In contrast, in-
creased lipid peroxidation was observed 
after the TCA impiramine. These findings 
point to a likely neuroprotective properties 
for some of the SSRIs. In this context, stud-
ies have shown that the SSRIs fluoxetine 
and paroxetine lessened the loss of nigral 
dopaminergic neurons caused by lipopoly-
scaccharide or by 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) (Chung 
et al., 2010a, b), while escitalopram pro-
tected against ischemia-induced neuronal 
death in the gerbil hippocampal CA1 region 
after transient cerebral ischemia (Lee et al., 
2011). These effects were mediated through 
decreased microglia activation, reactive 
oxygen species generation and oxidative 
stress. Studies also have shown reduced 
lipid and protein oxidation, in rat brain, in-
creased superoxide dismutase and catalse 
activities by imipramine (Réus et al., 2010). 
In culture, fluoxetine and amitriptyline, a 
tricyclic agent protected rat pheochromocy-
toma (PC12) cells from neurotoxicity of 
hydrogen peroxide and increased superox-
ide dismutase activity (Kolla et al. 2005). In 
vitro also, imipramine increased the sur-
vival rate of neural stem cells and prevented 
the endotoxin-induced apoptosis (Peng et 
al., 2008).  
In the current study, GSH which is de-
creased by endotoxin administration, is in-
creased in the brain by both the SSRIs and 
imipramine. Glutathione, an intracellular 
tripeptide (glycyl–glutamic acid–cysteine) 
is the most abundant sulfhydryl-containing 
compound in the cells and the brain’s most 
important cellular free radical scavenger 
(Wang and Ballatori, 1998; Wu et al., 
2004). The increments in reduced glu-
tathione by antidepressant drugs seem to 
correlate with their effect on lipid peroxida-
tion. For example, the increase in brain 
level of MDA by LPS endotoxin was de-
creased by the lower dose of fluoxetine, 
which also increased glutathione, suggest-
ing an antioxidant effect. In contrast, MDA 
was not altered by the higher dose of 
fluoxetine which also had no significant 
effect on reduced glutathione, suggesting an 
increased free radical production with the 
higher dose of the antidepressant drug. The 
TCA imipramine elicited marked increase 
in reduced glutathione at a dose which did 
not alter brain lipid peroxidation. Mean-
while, a lesser increase in reduced glu-
tathione was observed at the higher dose of 
imipramine which markedly enhanced lipid 
peroxidation in brain. Nevertheless, an in-
crease in reduced glutathione by antidepres-
sant drugs is important, since decreased 
glutathione content has been reported in 
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brain of patients suffering from a number of 
neurological diseases (Schulz et al., 2000; 
Dean et al., 2009; Gawryluk et al., 2011), 
thereby implicating GSH consumption by 
free radicals in the pathogenesis of these 
disorders.  
Within the central nervous system, ni-
tric oxide is an important physiological sig-
naling molecule involved in neurotransmis-
sion and control of vascular tone, but when 
generated in excess, neurotoxicity might 
ensue (Brown, 2010). Nitric oxide is gener-
ated by inflammatory cytokines due to the 
action of inducible nitric oxide (iNOS) 
(Moncada and Bolaños, 2006). In the pre-
sent study, the administration of LPS en-
dotoxin resulted in increased nitric oxide in 
brain. Other studies implicated nitric oxide 
in the induction of fever (Kozak and Kozak, 
2003) and in activation of apoptotic path-
ways in the brain during systemic inflam-
mation induced by lipopolysaccharide 
(Czapski et al., 2007). Furthermore, LPS-
activated microglia were shown to mediate 
oligodendrocyte progenitor cell death in-
volving nitric oxide-dependent oxidative 
pathway (Pang et al., 2010). The results of 
the present study demonstrate that the rise 
in nitric oxide in brain due to LPS is mark-
edly reduced by treatment with the SSRIs 
fluoxetine, sertraline and fluvoxamine. One 
notable observation was the reduction of 
nitric oxide by the lower dose of imipra-
mine which did not alter brain lipid peroxi-
dation. This finding contrasted with the in-
crease in nitric oxide by the higher dose of 
the drug which also elicited marked in-
crease in lipid peroxidation, suggesting a 
role for nitric oxide in this latter process. 
Several antidepressant drugs have been 
shown to modulate nitric oxide levels in 
brain. For example, imipramine has been 
reported to decrease nitrite/nitrate concen-
tration in brain (Krass et al., 2011) and ni-
tric oxide production in INF-γ stimulated 
microglia cells (Hashioka et al., 2007). In 
vivo, imipramine decreased nitric oxide 
synthase activity and nitrite in rat brain 
(Harvey et al., 2006; Liu et al., 2011). Flu-
oxetine has been reported to have no effect 
on brain nitrite/nitrate (Krass et al., 2011), 
to increase mRNA expression of iNOS 
(NOS2) (Ha et al., 2006) or to inhibit en-
dotoxin-induced release of nitric oxide, 
iNOS mRNA (Liu et al., 2011). Sertraline 
inhibited the generation of nitric oxide from 
INF-γ activated microglia (Horikawa et al., 
2010). 
The current study also investigated the 
effect of antidepressant drugs on oxidative 
status of the liver after treatment with LPS 
endotoxin. Similar to the findings that were 
observed in the brain, systemic endotoxae-
mia increased liver oxidative stress, in-
creased lipid peroxidation, decreased re-
duced glutathione and increased nitric oxide 
generation in the liver. These biochemical 
alterations were ameliorated to a large ex-
tent by antidepressant drugs. The present 
findings are in accordance with other stud-
ies suggesting a beneficial effect of a num-
ber of antidepressant drugs in reducing ex-
perimental hepatic injury (Abdel-Salam et 
al., 2006, 2010a, b, 2011). Several mecha-
nisms are likely to contribute to the effect 
of antidepressant drugs and in particular the 
SSRIs on the development of hepatic in-
jury. These agents decrease oxidative stress 
in the liver as seen in the present study. Re-
duced glutathione is increased and nitric 
oxide levels decreased following the ad-
ministration of antidepressant drugs. In the 
liver, nitric oxide is involved in regulation 
of hepatic haemodynamics (Mittal et al., 
1994; Lhuillier et al., 2006) and in hepatic 
regeneration (Tuncyurek et al., 2006). Stud-
ies indicated that inhibition of nitric oxide 
synthase increased hepatic lipid peroxida-
tion, serum liver enzymes and bilirubin in 
CCl4-intoxicated rats (Muriel, 1998), while 
increasing nitric oxide availability with L-
arginine improved hepatic arterial and por-
tal blood flow and sinusoidal oxygenation 
in experimental hepatic steatosis (Ijaz et al., 
2005). The increase in nitric oxide and con-
sequent vasodilatation can benefit tissue 
function against toxic insults, but another 
consequence of the elevated levels of nitric 
oxide is its cellular toxicity resulting in in-
creased lipid peroxidation. This is because 
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of the ability of nitric oxide to react with 
biomolecules or with other free radicals 
e.g., superoxide anion, yielding the highly 
reactive peroxynitrite radical capable of 
evoking the oxidation of important cellular 
biomolecules (Moncada et al., 1991; Daw-
son and Dawson,1996).  
It is to be noted also that antidepressant 
drugs possess anti-inflammatory properties 
(Bianchi et al., 1995) and have been shown 
to inhibit pro-inflammatory cytokines such 
as interleukin (IL)-1β, IL-6 and tumour ne-
crosis factor (TNF-α) (Hwang et al., 2008; 
Horikawa et al., 2010; Liu et al., 2011); 
these effect are likely to benefit the liver 
against toxic injury. Moreover, the effect of 
antidepressant drugs and in particular the 
SSRIs on serotonin metabolism is likely to 
contribute to their hepatic effects. Since 
these agents inhibit platelet aggregation and 
dense granule release (Serebruany et al., 
2001; Maurer-Spurej et al., 2004), they 
might act to reduce the vasoconstrictor ef-
fect of platelet-derived serotonin on the he-
patic microcirculation (Reilly et al., 1984; 
Murata et al., 2003; Nocito et al., 2007) 
which would benefit hepatic function. In 
contrast to other antidepressant drugs such 
as the SSRIs, the tertiary amine tricyclics, 
possess anticholinergic and antihistaminic 
properties and TCA have been shown to 
possess arterial vaso-relaxant properties 
(Vila et al., 1999). 
In conclusion, the present study sug-
gested a beneficial effect for the SSRIs 
fluoxetine, sertraline and fluvoxamine in 
reducing oxidative stress in brain and liver 
during mild systemic inflammatory illness 
induced by peripheral bacterial endotoxin 
injection.  
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